Clinical genetics in interstitial lung disease

Chad Alan Newton M.D., Philip L. Molyneaux, Justin M. Oldham

Research output: Contribution to journalReview article

Abstract

Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal lung processes with overlapping clinical, radiographic, and histopathologic features. Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF remains elusive, but a variety of genetic and infectious risk factors have been identified. CHP results from chronic inhalation of an organic antigen, usually of avian or mold origin, and may occur in patients with a genetic predisposition. While IPF is treated with anti-fibrotic compounds, CHP is generally treated by suppression of the immune system and elimination of the causative antigen. Despite advances in our understanding of IPF and CHP, there exists substantial variability in the diagnosis and treatment of these disease processes. Furthermore, IPF and CHP natural history and treatment response remain far from uniform, leaving it unclear which patients derive the most benefit from disease-specific therapy. While clinical prediction models have improved our understanding of outcome risk in patients with various forms of ILD, recent advances in genomic technology provides a valuable opportunity to begin understanding the basis for outcome variability. Such advances will ultimately allow for the incorporation of genomic markers into risk stratification and clinical decision-making. In this piece, we highlight recent advances in our understanding of the genomic factors that influence susceptibility and outcome risk among patients with IPF and CHP. Genomic modalities used to identify these genomic markers include genome-wide association studies, analyses of gene expression, drug-gene interaction testing, telomere length determination, telomerase mutation analysis, and studies of the lung microbiome. We then identify gaps in knowledge that should be addressed to help facilitate the incorporation of these genomic technologies into ILD clinical practice.

Original languageEnglish (US)
Article number116
JournalFrontiers in Medicine
Volume5
Issue numberAPR
DOIs
StatePublished - Apr 1 2018

Fingerprint

Extrinsic Allergic Alveolitis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases
Genome-Wide Association Study
Technology
Antigens
Lung
Telomerase
Microbiota
Telomere
Genetic Predisposition to Disease
Natural History
Drug Interactions
Inhalation
Names
Immune System
Fungi
Therapeutics
Gene Expression
Mutation

Keywords

  • Genomics
  • Hypersensitivity pneumonitis
  • Idiopathic interstitial pneumonia
  • Idiopathic pulmonary fibrosis
  • Interstitial lung disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical genetics in interstitial lung disease. / Newton M.D., Chad Alan; Molyneaux, Philip L.; Oldham, Justin M.

In: Frontiers in Medicine, Vol. 5, No. APR, 116, 01.04.2018.

Research output: Contribution to journalReview article

Newton M.D., Chad Alan ; Molyneaux, Philip L. ; Oldham, Justin M. / Clinical genetics in interstitial lung disease. In: Frontiers in Medicine. 2018 ; Vol. 5, No. APR.
@article{c9c2edf39ff245d99750fffe2d417aa4,
title = "Clinical genetics in interstitial lung disease",
abstract = "Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal lung processes with overlapping clinical, radiographic, and histopathologic features. Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF remains elusive, but a variety of genetic and infectious risk factors have been identified. CHP results from chronic inhalation of an organic antigen, usually of avian or mold origin, and may occur in patients with a genetic predisposition. While IPF is treated with anti-fibrotic compounds, CHP is generally treated by suppression of the immune system and elimination of the causative antigen. Despite advances in our understanding of IPF and CHP, there exists substantial variability in the diagnosis and treatment of these disease processes. Furthermore, IPF and CHP natural history and treatment response remain far from uniform, leaving it unclear which patients derive the most benefit from disease-specific therapy. While clinical prediction models have improved our understanding of outcome risk in patients with various forms of ILD, recent advances in genomic technology provides a valuable opportunity to begin understanding the basis for outcome variability. Such advances will ultimately allow for the incorporation of genomic markers into risk stratification and clinical decision-making. In this piece, we highlight recent advances in our understanding of the genomic factors that influence susceptibility and outcome risk among patients with IPF and CHP. Genomic modalities used to identify these genomic markers include genome-wide association studies, analyses of gene expression, drug-gene interaction testing, telomere length determination, telomerase mutation analysis, and studies of the lung microbiome. We then identify gaps in knowledge that should be addressed to help facilitate the incorporation of these genomic technologies into ILD clinical practice.",
keywords = "Genomics, Hypersensitivity pneumonitis, Idiopathic interstitial pneumonia, Idiopathic pulmonary fibrosis, Interstitial lung disease",
author = "{Newton M.D.}, {Chad Alan} and Molyneaux, {Philip L.} and Oldham, {Justin M.}",
year = "2018",
month = "4",
day = "1",
doi = "10.3389/fmed.2018.00116",
language = "English (US)",
volume = "5",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Clinical genetics in interstitial lung disease

AU - Newton M.D., Chad Alan

AU - Molyneaux, Philip L.

AU - Oldham, Justin M.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal lung processes with overlapping clinical, radiographic, and histopathologic features. Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF remains elusive, but a variety of genetic and infectious risk factors have been identified. CHP results from chronic inhalation of an organic antigen, usually of avian or mold origin, and may occur in patients with a genetic predisposition. While IPF is treated with anti-fibrotic compounds, CHP is generally treated by suppression of the immune system and elimination of the causative antigen. Despite advances in our understanding of IPF and CHP, there exists substantial variability in the diagnosis and treatment of these disease processes. Furthermore, IPF and CHP natural history and treatment response remain far from uniform, leaving it unclear which patients derive the most benefit from disease-specific therapy. While clinical prediction models have improved our understanding of outcome risk in patients with various forms of ILD, recent advances in genomic technology provides a valuable opportunity to begin understanding the basis for outcome variability. Such advances will ultimately allow for the incorporation of genomic markers into risk stratification and clinical decision-making. In this piece, we highlight recent advances in our understanding of the genomic factors that influence susceptibility and outcome risk among patients with IPF and CHP. Genomic modalities used to identify these genomic markers include genome-wide association studies, analyses of gene expression, drug-gene interaction testing, telomere length determination, telomerase mutation analysis, and studies of the lung microbiome. We then identify gaps in knowledge that should be addressed to help facilitate the incorporation of these genomic technologies into ILD clinical practice.

AB - Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal lung processes with overlapping clinical, radiographic, and histopathologic features. Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF remains elusive, but a variety of genetic and infectious risk factors have been identified. CHP results from chronic inhalation of an organic antigen, usually of avian or mold origin, and may occur in patients with a genetic predisposition. While IPF is treated with anti-fibrotic compounds, CHP is generally treated by suppression of the immune system and elimination of the causative antigen. Despite advances in our understanding of IPF and CHP, there exists substantial variability in the diagnosis and treatment of these disease processes. Furthermore, IPF and CHP natural history and treatment response remain far from uniform, leaving it unclear which patients derive the most benefit from disease-specific therapy. While clinical prediction models have improved our understanding of outcome risk in patients with various forms of ILD, recent advances in genomic technology provides a valuable opportunity to begin understanding the basis for outcome variability. Such advances will ultimately allow for the incorporation of genomic markers into risk stratification and clinical decision-making. In this piece, we highlight recent advances in our understanding of the genomic factors that influence susceptibility and outcome risk among patients with IPF and CHP. Genomic modalities used to identify these genomic markers include genome-wide association studies, analyses of gene expression, drug-gene interaction testing, telomere length determination, telomerase mutation analysis, and studies of the lung microbiome. We then identify gaps in knowledge that should be addressed to help facilitate the incorporation of these genomic technologies into ILD clinical practice.

KW - Genomics

KW - Hypersensitivity pneumonitis

KW - Idiopathic interstitial pneumonia

KW - Idiopathic pulmonary fibrosis

KW - Interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=85062717750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062717750&partnerID=8YFLogxK

U2 - 10.3389/fmed.2018.00116

DO - 10.3389/fmed.2018.00116

M3 - Review article

C2 - 29755982

AN - SCOPUS:85062717750

VL - 5

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

IS - APR

M1 - 116

ER -